Alignment Healthcare (NASDAQ:ALHC) CEO John Kao Sells 27,400 Shares of Stock

Key Points

• CEO John Kao sold 27,400 shares of Alignment Healthcare at an average price of $13, generating $356,200; the transaction occurred under a pre-arranged Rule 10b5-1 trading plan and reduced his stake by 4.43%.
• ALHC shares fell to $8.71, near their one-year low of $8.52, while trading volume reached roughly 24.3 million shares. The stock remains well below its 50-day and 200-day moving averages.
• Despite the selloff, the company recently beat quarterly earnings and revenue estimates, and analysts maintain a consensus “Moderate Buy” rating with an average price target of $23.60; investors remain focused on Medicare Advantage rule changes and potential star-rating risks.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John Kao sold 27,400 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.00, for a total value of $356,200.00. Following the sale, the chief executive officer owned 590,766 shares in the company, valued at $7,679,958. The trade was a 4.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Price Performance

Shares of Alignment Healthcare stock traded down $1.66 during trading on Wednesday, reaching $8.71. The company's stock had a trading volume of 24,295,330 shares, compared to its average volume of 4,811,371. The stock has a 50-day moving average price of $15.66 and a two-hundred day moving average price of $17.90. The stock has a market capitalization of $1.81 billion, a P/E ratio of 45.84 and a beta of 1.11. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 1.22. Alignment Healthcare, Inc. has a one year low of $8.52 and a one year high of $25.12.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.04. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The company's revenue was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS. As a group, sell-side analysts anticipate that Alignment Healthcare, Inc. will post 0.17 EPS for the current fiscal year.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Brokerages maintain an overall “Moderate Buy” recommendation, indicating that analysts generally view the recent decline as potentially creating an attractive entry point if Alignment’s operating outlook remains intact. Alignment Healthcare Given Average Recommendation of Moderate Buy
• Positive Sentiment: Unusually heavy call-option activity—19,456 calls purchased versus typical volume of about 1,775—shows that some traders are positioning for a potential rebound, although options activity is speculative and does not change the company’s fundamentals.
• Neutral Sentiment: Alignment Healthcare’s exposure to new Medicare Advantage rule changes is drawing investor attention. The effect on revenue, benefits, reimbursement, and costs will depend on the final rules and the company’s ability to adapt. How Could Alignment Healthcare Handle New Medicare Advantage Rule Changes?
• Negative Sentiment: Investors reacted negatively to management’s Baird conference comments and apparent reluctance to discuss star ratings. The lack of clarity was interpreted as a possible warning regarding future Medicare Advantage quality ratings, which can affect member enrollment, reimbursement, and profitability. Alignment falls after comments at Baird investor conference
• Negative Sentiment: Several law firms, including Hagens Berman, Frank R. Cruz, and Rosen Law Firm, announced or continued investigations into potential securities-law violations following the selloff. These announcements increase headline and litigation risk, although they contain allegations rather than established findings. Hagens Berman updates Alignment Healthcare investigation
• Negative Sentiment: A reported insider sale of approximately $7.1 million may add to investor concern about management confidence, though the filing alone does not establish the reason for the transaction. Alignment Healthcare insider sold shares

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALHC. JPMorgan Chase & Co. dropped their price objective on shares of Alignment Healthcare from $26.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. KeyCorp reiterated an "overweight" rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Zacks Research cut Alignment Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Barclays dropped their target price on Alignment Healthcare from $19.00 to $16.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 26th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Alignment Healthcare in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Alignment Healthcare has a consensus rating of "Moderate Buy" and an average price target of $23.60.

Hedge Funds Weigh In On Alignment Healthcare

Large investors have recently bought and sold shares of the business. Allworth Financial LP lifted its stake in Alignment Healthcare by 8.9% in the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company's stock valued at $137,000 after acquiring an additional 566 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Alignment Healthcare by 9.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 11,445 shares of the company's stock worth $202,000 after acquiring an additional 962 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Alignment Healthcare by 46.6% in the second quarter. GAMMA Investing LLC now owns 3,368 shares of the company's stock valued at $80,000 after purchasing an additional 1,070 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of Alignment Healthcare by 463.3% in the second quarter. Versant Capital Management Inc now owns 1,380 shares of the company's stock valued at $33,000 after purchasing an additional 1,135 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of Alignment Healthcare in the second quarter worth $36,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled healthcare company that provides Medicare Advantage health plans and care-management services for older adults. Through its Alignment Health Plan subsidiary, the company offers insurance coverage designed for Medicare-eligible members, including primary and specialty care coordination, prescription drug benefits, preventive services and access to a network of healthcare providers.

The company combines health-plan operations with proprietary technology intended to support personalized care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.